Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma

Relapsed and refractory multiple myeloma (RRMM) is a plasma cell neoplasm defined by progressively refractory disease necessitating chronic and increasingly intensive therapy. Despite recent advances, limited treatment options exist for RRMM. This single-arm, open label phase 1 study aimed to evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: Frigault, Matthew J., Bishop, Michael R., Rosenblatt, Jacalyn, O’Donnell, Elizabeth K., Raje, Noopur, Cook, Daniella, Yee, Andrew J., Logan, Emma, Avigan, David E., Jakubowiak, Andrzej, Shaw, Kit, Daley, Heather, Nikiforow, Sarah, Griffin, Faith, Cornwell, Christine, Shen, Angela, Heery, Christopher, Maus, Marcela V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989524/
https://www.ncbi.nlm.nih.gov/pubmed/35468618
http://dx.doi.org/10.1182/bloodadvances.2022007210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989524/
https://www.ncbi.nlm.nih.gov/pubmed/35468618
http://dx.doi.org/10.1182/bloodadvances.2022007210

Ejemplares similares